Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15917988 | 0.92 | PARP1 (0.67) | PARP1 | |
| SCHEMBL15918721 | 0.92 | PARP1 (0.49) | PARP1MAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL14233392 | 0.90 | PARP1 (0.69) | PARP1MAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL15917663 | 0.87 | PARP1 (0.69) | PARP1 | |
| SCHEMBL15918647 | 0.85 | PARP1 (0.69) | PARP1 | |
| SCHEMBL15917434 | 0.84 | PARP1 (0.51) | PARP1 | |
| SCHEMBL15917731 | 0.83 | PARP1 (0.68) | PARP1 | |
| SCHEMBL15918446 | 0.83 | PARP1 (0.58) | PARP1 | |
| SCHEMBL15917567 | 0.83 | PARP1 (0.69) | PARP1 | |
| SCHEMBL14233393 | 0.82 | PARP1 (0.80) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2022-02-15 | — | — | US | claimed |
| EP-3925962-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE | Rakovina Therapeutics Inc. (CA) | 2021-12-22 | — | — | EP | claimed |
| EP-2714703-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2021-03-10 | — | — | EP | claimed |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | claimed |
| US-20140221314-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | claimed |
| US-12612425-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2026-04-28 | — | — | US | disclosed |
| US-20230027257-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | KANION USA INC. | 2023-01-26 | — | — | US | disclosed |
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2022-02-15 | — | — | US | disclosed |
| EP-3925962-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE | Rakovina Therapeutics Inc. (CA) | 2021-12-22 | — | — | EP | disclosed |
| EP-2714703-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | RAKOVINA THERAPEUTICS INC. (CA) | 2020-09-24 | — | — | US | disclosed |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20140221314-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221314-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | PARP1 1/4885MAP4K4 1634/4885CLK2 931/4885 |
| US-20230027257-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | PARP1 1/4885MAP4K4 1634/4885CLK2 931/4885 |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | PARP1 1/4885MAP4K4 1634/4885CLK2 931/4885 |
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | PARP1, PARP2, PARP11 | PARP1 1/4885MAP4K4 1634/4885CLK2 931/4885 |
| US-12612425-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | PARP1, PARP2, PARP11 | PARP1 1/4885MAP4K4 4305/4885CLK2 2446/4885 |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | PARP1 1/4885MAP4K4 1726/4885CLK2 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.